Home
overview
Obesity is fast becoming a modern-day epidemic, and with direct links to diabetes and the metabolic syndrome, it has been tagged by the U.S administration a ‘public health crisis’.
However, existing obesity therapeutics have failed to meet the overwhelming market demand, often accompanied by significant side-effects and demonstrating only marginal weight loss.
  
The 2007 Targeting Obesity Conference examines the latest developments in the research of therapeutics for Obesity and related disorders:
   
  • Seeking greater efficacy in existing obesity treatments
  • Successful target identification and innovative approaches
  • Overcoming the challenges of adverse side-effects

The event brings together Vice Presidents, Directors, and leading Researchers from the pharmaceutical industry to share successes and discuss the critical issues surrounding the development of innovative solutions.
   
Confirmed speakers include:
  • Dr Douglas Greene, Vice President, Regulatory Development, Sanofi-Aventis
  • Dr Marcus Schindler, Director, Metabolic Diseases Research, Boehringer-Ingelheim
  • Dr Marc Reitman, Director, Metabolic Disorders, Merck
  • Dr Glenn Matfin, Head, US Medical Affairs, Novo Nordisk
  • Dr Uwe Gudat, Global Brand Medical Director, Dyslipidemia and Diabetes, Novartis
  • Dr Michael Trautmann, Medical Fellow, Clinical Investigation, Eli Lilly

  

Who Should Attend the SMi Targeting Obesity Conference?

  • Medical Directors
  • Director of Metabolic Diseases
  • Senior Scientists - Metabolic and Cardiovascular Diseases
  • Directors of Clinical Research
  • Senior Clinical Project Managers

   
Targeting Obesity Conference offers a unique opportunity to hear about the latest developments from industry leaders. Bringing together knowledge and expertise, it’s designed to create the perfect setting for the exchange of ideas and networking opportunities.
                                                                                                                
For Speaking opportunities please contact Venus Simbulan at vsimbulan@smi-online.co.uk
For Sponsorship opportunities please contact Martin Cawte at mcawte@smi-online.co.uk

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Prof Mike Cawthorne

Prof Mike Cawthorne, Director of Metabolic Research, Clore Laboratory, University of Buckingham

9:10 EXENATIDE AND INCRETIN MIMETICS

Dr Michael Trautmann

Dr Michael Trautmann, Medical Fellow, Clinical Investigations, Eli Lilly

  • Actions of GLP-1 and incretin mimetics beyond stimulating insulin release
  • Effects on appetite and food intake
  • Improved glucose control in overweight patients with Type 2 Diabetes
  • Long term weight effects in Diabetes patients
  • What is known about incretin mimetic effects in non-diabetic people
  • 9:50 REDUCING CALORIE INTAKE THROUGH APPETITE REGULATION

    Prof Stephen Bloom

    Prof Stephen Bloom, Founder and Chief Scientific Officer , Thiakis

  • Need for further agents
  • Natural appetite regulating pathways are the safest therapeutic entry point
  • Gut hormones act both accutely after meals and chronically in gut disease to limit appetite
  • Choice of Ghrelin inhibitors, pancreatic polypeptide (PP), PYY3-36, GLP-1 and oxyntomodulin type agents
  • Methods of delivery critical for practical peptide therapies
  • 10:30 Morning Coffee

    11:00 NEUROHORMONAL APPROACH TO TREATING OBESITY

    Dr David Maggs

    Dr David Maggs, Vice President, Medical Affairs, Amylin Pharmaceuticals

  • Review of neurohormonal systems regulating body weight control
  • Evidence for impacting pathophysiology
  • New treatment plan
  • 11:40 “LEAN GENES” AS POTENTIAL TARGETS FOR OBESITY TREATMENT

    Dr Itzhak Harosh

    Dr Itzhak Harosh, Chairman and Chief Scientist Officer, ObeTherapy

  • Why obesity genes do not deliver an answer for obesity treatment
  • The “thrifty genotype” and the “expenditure genotype” as possible clues for obesity treatments
  • Searching for “lean genes” in lean phenotype
  • 12:20 Networking Lunch

    14:00 REGULATORY APPROVAL FOR TREATING OBESITY AND THE METABOLIC SYNDROME

    Dr Douglas Greene

    Dr Douglas Greene, Senior Vice President and Chief Medical Office , Sanofi-Aventis

  • Are anti-obesity compounds viewed as a ‘lifestyle drug’?
  • Pathways for the pharmaceutical industry towards accelerated approval
  • 14:40 PHARMACOGENOMIC APPROACHES FOR OBESITY DRUG THERAPY

    Dr Marc Reitman

    Dr Marc Reitman, Director, Metabolic Disorders, Merck Research Laboratories

  • Possible uses for pharmacogenomics
  • Application to obesity and diabetes
  • 15:20 MELANOCORTIN 4 RECEPTOR (MC4R) AGONISTS AS POTENTIAL ANTI-OBESITY THERAPEUTICS

    Dr Alison M Strack

    Dr Alison M Strack, Senior Research Fellow, Department of Pharmacology, Merck Research Laboratories

  • MC4R as the currently single known CNS GPCR to have both an endogenous agonist (a-MSH) and an endogenous antagonist (AGRP)
  • Complex regulation within the neural network regulating energy homeostasis
  • Selective MC4R agonists suppress feeding and increase energy expenditure, leading to decreased body weight and adiposity
  • 16:00 Chairman’s Closing Remarks and Close of Day One followed by Afternoon Tea

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Prof Mike Cawthorne

    Prof Mike Cawthorne, Director of Metabolic Research, Clore Laboratory, University of Buckingham

    9:10 THE PHARMACEUTICAL APPROACH TO OBESITY – ROADS TO PROGRESSION

    Prof Mike Cawthorne

    Prof Mike Cawthorne, Director of Metabolic Research, Clore Laboratory, University of Buckingham

  • Existing drugs and the search for greater efficacy
  • Satisfying the regulator, funder, doctor and patient
  • Is targeting lipid metabolism and energy expenditure a viable option?
  • 9:50 ANIMAL IN VIVO PHARMACOLOGY FOR CENTRAL MECHANISMS REGULATING FOOD INTAKE

    Dr Marcus Schindler

    Dr Marcus Schindler, Associate Director, Metabolic Diseases Research, Boehringer-Ingelheim

  • Comparative mechanisms governing food intake in rodents and humans
  • 10:30 Morning Coffee

    11:00 THE CHOICE OF ANIMAL MODELS IN EFFICACY VALIDATION

    Dr Philip J Larsen

    Dr Philip J Larsen, Chief Executive Officer, Rheoscience

  • The choice of animal models in efficacy validation of drugs targeting metabolic disorders  
  • 11:40 ANIMAL MODELS FOR FACETS OF THE METABOLIC SYNDROME

    Prof Ingrid Klöting

    Prof Ingrid Klöting, Researcher, Ernst-Moritz-Arndt University Greifswald

  • WOKW rats with polygenetical inherited facets of metabolic syndrome
  • Congenic rat strains define chromosomal regions for obesity in the rat
  • Are there candidate genes for obesity in these regions in rat and human?
  • 12:20 Networking Lunch

    13:50 OXYGEN AND PROTON FLUXES ENABLE KINETIC STUDIES OF FATTY ACID OXIDATION AND MITOCHONDRIAL FUNCTION

    Dr David Ferrick

    Dr David Ferrick, Vice President, Assay Development, Seahorse Bioscience

    14:30 CHALLENGES IN DEVELOPING THERAPIES FOR THE METABOLIC SYNDROME

    Dr Glenn Matfin

    Dr Glenn Matfin, Vice-President and Head, Global Medical and Scientific Affairs,, Takeda Pharmaceuticals Co

  • Registering mechanisms as treatments and the efficacy debate
  • The impact of recognizing the Metabolic Syndrome as a disease
  • 15:10 Afternoon Tea

    15:40 OPENSOURCE DIETS FOR METABOLIC DISEASE RESEARCH

    Matthew Ricci

    Matthew Ricci, Ph.D., Director of Project Management, Research Diets Inc.

    • Description of purified, OpenSource Diets and their use
    • Metabolic Disease Data Generated using OpenSource Diets
    • Global continuity of animal models

    16:20 SIRT1: A NOVEL TARGET FOR THE TREATMENT OF METABOLIC DISEASE

    Dr Jill Milne

    Dr Jill Milne, Senior Director, Biology, Sirtris Pharmaceuticals

    ·   Sirtuins and Type 2 Diabetes
    ·   SIRT1 and Calorie Restriction & Mitochondrial function
    ·   Discovery of small molecule SIRT1 activators

    17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Animal Models of Obesity to Study Therapeutic Control of Energy Balance
    Workshop

    Animal Models of Obesity to Study Therapeutic Control of Energy Balance

    Hesperia Victoria Hotel
    25th September 2007
    London, United Kingdom

    Hesperia Victoria Hotel

    2 Bridge Place
    Victoria
    London SW1V 1QA
    United Kingdom

    Hesperia Victoria Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.